To elucidate the immunological significance and regulatory mechanisms of CD244 in diffuse large B-cell lymphoma (DLBCL).
Approach:
Methods: Utilized single-cell and bulk RNA sequencing to analyze CD244 expression patterns, intracellular adaptor molecules, and correlations with immune checkpoints and metabolic alterations. Investigated clinical implications through immunohistochemistry and reverse …
Key Findings:
NK cells were the primary CD244-expressing population in DLBCL, co-overexpressing PDCD1, CTLA4, LAG3, TIGIT, PTGER4, and CD160.
Elevated CD244 expression correlated with an immunosuppressive tumor microenvironment, worse clinicopathological features, and poorer outcomes.
CD244 expression is associated with increased potential responsiveness to immune checkpoint blockade therapy.
EAT2 was identified as the predominant intracellular adaptor for CD244, indicating its role in NK cell metabolic dysregulation.
CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells.
Interpretation:
CD244 plays a critical role in NK cell dysfunction and DLBCL progression, suggesting its potential as a target for immunotherapy.
Limitations:
The study focused on a specific cohort of DLBCL patients, which may limit generalizability.
Further research is needed to fully understand the regulatory mechanisms of CD244 in DLBCL.
Conclusion:
The findings highlight the significance of CD244 in DLBCL.
